|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07K 16/28 | |
| A61K 39/395 | |||
| A61P 35/00 |
| (11) | Patento numeris | 2699598 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 12713849.3 |
| Europos patento paraiškos padavimo data | 2012-04-09 | |
| (97) | Europos patento paraiškos paskelbimo data | 2014-02-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-03-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2012/032704 |
| Data | 2012-04-09 |
| (87) | Numeris | WO 2012/145183 |
| Data | 2012-10-26 |
| (30) | Numeris | Data | Šalis |
| 201161477153 P | 2011-04-19 | US |
| (72) |
ELLIOTT, Mark William, US
FISHER, Timothy Scott, US
SHARP, Leslie Lynne, US
|
| (73) |
Pfizer Inc.,
235 East 42nd Street, New York, NY 10017,
US
|
| (54) | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER |
| COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INDUCING ANTIBODIES FOR THE TREATMENT OF CANCER |